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Background/Significance
• Up to 62% of individuals with cardiac conditions
continue to smoke, even after experiencing lifethreatening events (Colivicchi et al., 2011; Rea et al., 2002).

• Continued smoking among patients with existing
cardiac disorders or prior cardiac events is associated
with increased risk for subsequent fatal cardiac events
(Gerber, Rosen, Goldbourt, Benyamini, & Drory, 2009; Kinjo et al., 2005).

Smoking Cessation and Cardiology Patients
• Smoking cessation interventions associated with reduced
rates of premature death among cardiac patients (Van Berkel,
Boersma, Roos-Hesselink, Erdman, & Simoons, 1999).

• In a retrospective study of 3511 current smokers with acute
myocardial infarction (AMI) attending hospitals in Ontario,
only 52% were offered smoking cessation counseling. The
group of patients receiving smoking cessation counseling
was significantly less likely to experience mortality in the
year following hospitalization compared to those not
receiving counseling. (Van Spall et al., 2007)

Smoking cessation and cardiology patients
• A randomized controlled trial of a an intensive smoking
cessation programme compared to usual care among
cardiac patients found significantly higher 2-year continuous
abstinence rates in the intensive smoking cessation group
versus the usual care group (33% vs. 9%). (Mohiuddin et al., 2007).
•

Moreover mortality rate (all causes) was 2.8% in the
intensive smoking cessation group versus 12.0% in the
usual care group over the 2-year follow up period (Mohiuddin et
al., 2007).

• But few studies in Canada have examined outcomes of
delivering smoking cessation among cardiology patients.

Purpose
• Examine smoking cessation and reduction
outcomes of an intensive tobacco treatment
programme in cardiology services

• Examine predictors of smoking cessation

Intervention
• The SCC programme takes a longitudinal approach to
tobacco treatment, a process which has no set end-point.
• Pharmacotherapy. A recommendation for the use of
pharmacotherapy is provided to all participants. Options
include NRT (i.e., nicotine gum, patch, lozenge, inhaler or
oral spray), varenicline or buproprion SR. Combinations of
these products are frequently utilized. A medication
protocol was established for the SCC programme based on
existing treatment algorithms for the use of
pharmacotherapy in clinics and outpatient settings (Bader,
McDonald, & Selby, 2009).

Participants and Sample
N = 145
Attended initial clinic visit between
(September 16th, 2010 to May 24th, 2012

n = 28
Not engaged participants
(i.e., did not return for a followup visit beyond initial
assessment)

117
Intent to treat

n = 93

n = 12

n = 12

Cardiology services

Respirology Services

Other sources

(referred by cardiology providers,
cardiac and heart fibrillation clinics,
and catheterization/ stress/
echocardiogram labs)

(referred by respirology
providers, chronic obstructive
pulmonary disease transition,
and lung clinics)

(referred by other hospital
services [i.e., men’s health,
urology, neurology, arthritis
clinic] and general practice
providers, and self-referrals)

Sample Characteristics (n = 117)
History of a Psychiatric or
Substance use disorder?

Gender

24.8%

33.6%

20.5%

66.4%

Female

34.2%

20.5%

Neither

Psychiatric only

Substance use only

Both

Male

7.7%

26.5%

Income Sources

100

3.4%

62.4%

Pre-contemplative
Preparation
Action

Smoking Cessation Stage of Change

Percent %

Contemplative

80
60
40
20

0

30.2%

31.0%

38.8%

Sample Characteristics (contd.)
Mean

Stand. Dev.

Age of participant (years)

58.5

10.5

Age at smoking initiation (years)

16.4

4.4

Importance of quitting (scale of 0 ‘low’ to 10 ‘high’)

8.6

2.0

Confidence in quitting (scale of 0 ‘low’ to 10 ‘high’)

6.3

2.6

Number of cigarettes smoked per day

15.9

8.0

Fagerstrom Test for Nicotine Dependence

4.2

2.4

Number of medical co-morbidities

2.8

1.3

CO level at baseline (ppm)

15.8

9.6

Average number of visits to the programme

5.0

3.3

Length of time in the programme (in weeks)

19.1

16.2

(scale of 0 ‘low’ to 10 ‘high’)

Smoking Cessation outcomes by referral source
100.0

Percent %

80.0

60.0

40.0

36.6

33.3

35.0
25.0

20.0

0.0

Cardiology
(n = 93)

Respirology
(n = 12)

Other source
(n = 12)

Total sample
(n = 117)

Note. No significant difference in cessation outcomes by referral source (χ2=0.64, p = .785)

Smoking reduction outcomes by referral source
100.0

Percent %

80.0
60.0

42.4

50.0
33.3

40.0

42.1

20.0
0.0

Cardiology
(n = 59)

Respirology
(n = 8)

Other source
(n = 9)

Total sample
(n = 76)

Note. No significant difference in cessation outcomes by referral source (χ2=0.49, p = .783)

Smoking cessation by time engaged in the
programme (n = 117)
100

71.4

Percent %

80

48.1

60

34.3
40

23.3

22.2

20

0

1 month or
less (n = 18)

1-3 months
(n = 35)

3-6 months
(n = 30)

6-12 months
(n = 27)

> 1 year
(n = 7)

Note. Significant linear trend with greater likelihood of cessation with longer
engagement in programme (χ2 = 5.2 [df = 1], p = .023)

Duration of abstinence among those who
achieved cessation (n = 41)
100

Percent %

80

60

40

29.4

36.6

22.0

23.3

20

0

1 month or less
(n = 12)

1-3 months
(n = 9)

3-5 months
(n = 5)

> 5 months
(n = 15)

Multivariate associationsa of smoking cessation during
analysis period (n = 117)
Predictors

Odds Ratio

95%CI

Gender
Male (referent)
Female

1.0
.3*

.1-1.0

Stage of Change
Precontemplative/Contemplative (referent)
Preparation/Action

1.0
3.3

1.0-11.3

1.1

.9-1.3

.9

.7-1.1

.9

.9-1.0

1.0**

1.0-1.1

Confidence in quitting

FTND at baseline
Expired CO level at baseline
Length of time in the programme (in weeks)
a

Hosmer and Lemeshow goodness-of-fit test χ2 = 3.2 [df = 8], p = .923

* = p <.05, ** = p <.001, *** = p <.001

Summary of Key Findings
• Smoking abstinence/cessation outcomes:
– Cessation among those engaged in the programme: 35.5%(41/117)
– Reduction among those unable to achieve abstinence: 42.1% (32/76)

• Significant predictors of abstinence :
– Being male.
– Attending the SCC program for a longer duration.

• Limitations:
– Retrospective analysis design
– Use of 7-day point prevalence abstinence as measure of smoking
cessation outcome
– Analysis of existing data (missing variables such as education level)
– Relatively low sample size (n = 117)
– Patients motivated to quit smoking, self-selection bias

Conclusions/Implications
• Need for tobacco treatment programmes within hospital
settings.

• Consideration of a longitudinal approach to tobacco
treatment

